ENTRY       D10836            Mixture   Drug
NAME        Emtricitabine, rilpivirine and tenofovir alafenamide;
            Odefsey (TN)
PRODUCT     ODEFSEY (Gilead Sciences)
COMPONENT   Emtricitabine [DR:D01199], (Rilpivirine hydrochloride [DR:D09958] | Rilpivirine [DR:D09720]), (Tenofovir alafenamide fumarate [DR:D10605] | Tenofovir alafenamide [DR:D10428])
CLASS       Antiviral
             DG03107  Anti-HIV agent
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
            Transporter substrate
             DG01665  ABCB1 substrate
             DG03001  CTSA substrate
REMARK      Therapeutic category: 6250
            ATC code: J05AR19
            Product: D10836<JP/US>
EFFICACY    Antiviral
  DISEASE   HIV-1 infection [DS:H01563]
COMMENT     Rilpivirine is primarily metabolized by CYP3A.
            Tenofovir alafenamide is a substrate of cathepsin A, CYP3A and P-gp.
TARGET      HIV-1 reverse transcriptase [KO:K24802]
METABOLISM  Enzyme: CTSA [HSA:5476], CYP3A [HSA:1576 1577 1551]
            Transporter: ABCB1 [HSA:5243]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AR Antivirals for treatment of HIV infections, combinations
                 J05AR19 Emtricitabine, tenofovir alafenamide and rilpivirine
                  D10836  Emtricitabine, rilpivirine and tenofovir alafenamide &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-HIV Combinations
               Emtricitabine/ Rilpivirine/ Tenofovir Alafenamide Fumarate
                D10836  Emtricitabine, rilpivirine and tenofovir alafenamide
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D10836  Emtricitabine, rilpivirine and tenofovir alafenamide
            Drug groups [BR:br08330]
             Antiviral
              DG03107  Anti-HIV agent
               D10836  Emtricitabine, rilpivirine and tenofovir alafenamide
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               D10836  Emtricitabine, rilpivirine and tenofovir alafenamide
             Transporter substrate
              DG01665  ABCB1 substrate
               D10836  Emtricitabine, rilpivirine and tenofovir alafenamide
              DG03001  CTSA substrate
               D10836  Emtricitabine, rilpivirine and tenofovir alafenamide
            Drug classes [BR:br08332]
             Antiviral
              DG03107  Anti-HIV agent
               D10836  Emtricitabine, rilpivirine and tenofovir alafenamide
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               HIV reverse transcriptase inhibitor
                D10836  Emtricitabine, rilpivirine and tenofovir alafenamide &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10836
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10836
             Drug transporters
              D10836
DBLINKS     PubChem: 319902636
///
